ESCITALOPRAM IN TREATMENT OF DISABILITY IN MAJOR DEPRESSIVE PATIENTS

被引：0
|
作者：
Zivkovic, N. [1 ]
Pavicevic, D. [1 ]
Djokic, G. [1 ]
机构：
[1] Inst Neuropsychiat Laza Lazarev, Belgrade, Serbia
来源：
EUROPEAN PSYCHIATRY | 2010年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Comparative efficacy of escitalopram and duloxetine in the acute treatment of major depressive disorder
    Bose, A.
    Gommoll, C.
    Li, D.
    Gandhi, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S349 - S350
  • [32] Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder
    Martens, Marieke A. G.
    Filippini, Nicola
    Harmer, Catherine J.
    Godlewska, Beata R.
    PSYCHOPHARMACOLOGY, 2022, 239 (11) : 3447 - 3460
  • [33] Tissue-Specific Oxysterols as Predictors of Antidepressant (Escitalopram) Treatment Response in Patients With Major Depressive Disorder
    Sun, Zuoli
    Yang, Jian
    Zhou, Jia
    Zhou, Jingjing
    Feng, Lei
    Feng, Yuan
    He, Yi
    Liu, Min
    Li, Yuhong
    Wang, Gang
    Li, Rena
    BIOLOGICAL PSYCHIATRY: GLOBAL OPEN SCIENCE, 2023, 3 (04): : 663 - 672
  • [34] Comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder
    Wade, A. G.
    Gembert, K.
    Florea, I.
    EUROPEAN PSYCHIATRY, 2008, 23 : S268 - S268
  • [35] Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder
    Marieke A. G. Martens
    Nicola Filippini
    Catherine J. Harmer
    Beata R. Godlewska
    Psychopharmacology, 2022, 239 : 3447 - 3460
  • [36] Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder
    Dominika Jarčušková
    Ivan Tkáč
    Nataša Hlaváčová
    Alena Stančáková Yaluri
    Miriam Kozárová
    Viera Habalová
    Lucia Klimčáková
    Jozef Židzik
    Martin Javorský
    Aneta Bednářová
    BMC Psychiatry, 24 (1)
  • [37] A randomized study of escitalopram and paroxetine controlled-release in the treatment of Japanese patients with major depressive disorder
    Kishi, T.
    Kawashima, K.
    Moriwaki, M.
    Otake, Y.
    Mukai, T.
    Matsuda, Y.
    Fujita, K.
    Iwata, N.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S338 - S338
  • [38] A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder
    Wade, A.
    Gembert, K.
    Florea, I.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (07) : 1605 - 1614
  • [39] Efficacy and Safety of Escitalopram in the Treatment of Major Depressive Disorder in Chinese Patients: A Meta-Analysis Study
    Gou, Mingyang
    2019 ASIA-PACIFIC CONFERENCE ON CLINICAL MEDICINE AND PUBLIC HEALTH (CMPH 2019), 2019, : 83 - 88
  • [40] Treatment with escitalopram improves the attentional bias toward negative facial expressions in patients with major depressive disorders
    Zhou, Zhenhe
    Cao, Suxia
    Li, Hengfen
    Li, Youhui
    JOURNAL OF CLINICAL NEUROSCIENCE, 2015, 22 (10) : 1609 - 1613
12345